Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    MagForce

    MCap

    —

    Last close

    -0.02

    ▲ 0.01 (100.00%)

    DFR Gold

    MCap

    CAD16m

    Last close

    CAD0.10

    ▲ 0.03 (42.86%)

    Context Therapeutics

    MCap

    USD17m

    Last close

    USD1.06

    ▲ 0.19 (21.84%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Kazia Therapeutics – Edison Open House interview

Kazia Therapeutics – Edison Open House interview

Associated equity: Kazia Therapeutics

Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.

View this company

Kazia Therapeutics — 9 videos in collection

< Previous
Next >

You may also be interested in these:

Healthcare

Kazia Therapeutics webinar - Combating childhood brain cancer

Healthcare

EVT801, Kazia’s second programme, and capital markets

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free